Search Results for "fondaparinux"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fondaparinux. Results 11 to 13 of 13 total matches.
See also: Arixtra

New Oral Anticoagulants for Acute Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2014  (Issue 1433)
weight heparin (LMWH), or fondaparinux (Arixtra, and generics); all are associated with similar rates ...
Anticoagulants are the drugs of choice for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE).
Med Lett Drugs Ther. 2014 Jan 6;56(1433):3-4 |  Show IntroductionHide Introduction

Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
anticoagulant such as unfractionated heparin, low molecular weight heparin (LMWH), or fondaparinux (Arixtra ...
The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):43-5 |  Show IntroductionHide Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
effect For treatment of VTE, requires overlap with LMWH, fondaparinux, or UFH for ≥5 days and until INR ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 |  Show IntroductionHide Introduction